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Abstract
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that induces a battery of cytoprotective genes
involved in antioxidant defense through binding to Antioxidant Response Elements (ARE) located in the promoter regions
of these genes. To identify Nrf2 activators for the treatment of oxidative/electrophilic stress-induced diseases, the present
study developed a high-throughput assay to evaluate Nrf2 activation using AREc32 cells that contain a luciferase gene
under the control of ARE promoters. Of the 47,000 compounds screened, 238 (top 0.5% hits) of the chemicals increased the
luminescent signal more than 14.4-fold and were re-tested at eleven concentrations in a range of 0.01–30 mM. Of these 238
compounds, 231 (96%) increased the luminescence signal in a concentration-dependent manner. Chemical structure
relationship analysis of these 231 compounds indicated enrichment of four chemical scaffolds (diaryl amides and diaryl
ureas, oxazoles and thiazoles, pyranones and thiapyranones, and pyridinones and pyridazinones). In addition, 30 of these
231 compounds were highly effective and/or potent in activating Nrf2, with a greater than 80-fold increase in luminescence,
or an EC50 lower than 1.6 mM. These top 30 compounds were also screened in Hepa1c1c7 cells for an increase in Nqo1
mRNA, the prototypical Nrf2-target gene. Of these 30 compounds, 17 increased Nqo1 mRNA in a concentration-dependent
manner. In conclusion, the present study documents the development, implementation, and validation of a high-
throughput screen to identify activators of the Keap1-Nrf2-ARE pathway. Results from this screening identified Nrf2
activators, and provide novel insights into chemical scaffolds that might prevent oxidative/electrophilic stress-induced
toxicity and carcinogenesis.
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Introduction
Oxidative stress is the consequence of imbalanced production of
reactive oxygen species (ROS) and the ability of cells to detoxify
these ROS, which can result in ROS-induced tissue damage. In
humans, oxidative stress is involved in the pathogenesis of
numerous clinical conditions, including atherosclerosis [1],
Alzheimer’s disease [2], and rheumatoid arthritis [3]. In addition,
ROS, together with other electrophiles, are capable of attacking
DNA in the nucleus increasing the risk of carcinogenesis [4].
The Kelch-like ECH-associated protein 1 (Keap1) - nuclear
factor, erythroid derived 2, like 2 (Nrf2) pathway serves as one of
the major protective mechanisms in cells in response to oxidative/
electrophilic stress. Under basal conditions, Nrf2 is sequestered in
the cytoplasm by the cytoskeletal anchoring protein Keap1, and is
targeted for ubiquitin-mediated proteasome degradation. Upon
the stimuli of oxidative/electrophilic stress, Nrf2 is released from
Keap1 and Nrf2 translocates into the nucleus [5]. Once in the
nucleus, Nrf2 heterodimerizes with a variety of transcriptional
regulatory proteins, including members of the activator protein-1
family (Jun and Fos), and the small Maf family of transcription
factors [6]. These protein complexes bind to antioxidant response
elements (ARE) located in the upstream promoter region of a
battery of genes, and drives their transcription [7].
The Nrf2 target genes are involved in a variety of cytoprotective
events, such as glutathione (GSH) synthesis and recycling (Gclc,
Gclm, Gss, Gsr), reduction of hydrogen peroxide (Gpx), reduction
of oxidized protein (Txn, Txnrd, Srxn), detoxification of
electrophiles (Nqo1, Gst), and excretion of GSH-conjugated
electrophiles (Mrp) [8]. Thus, it is not surprising that Nrf2
deficient mice are more susceptible, whereas Nrf2 enhanced mice
are resistant to chemical-induced oxidative/electrophilic stress and
subsequent tissue injury. For example, compared with wild-type
mice, Nrf2-null mice are more susceptible to acetaminophen-
induced liver injury [9], cigarette smoke-induced lung injury [10],
dextran sulfate sodium/azoxymethane-induced colitis and colo-
rectal cancer [11], and benzo[a]pyrene-induced forestomach
cancer [12]. In contrast, Keap1-knockdown and Keap1-hepatoc-
tye knockout mice, in which Nrf2 is constitutively activated, are
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highly resistant to acetaminophen [13], diquat [14], and cadmium
[15]-induced lethality and tissue injury. In addition, a number of
synthetic and natural compounds protect against oxidative/
electrophilic stress-induced toxicity, at least partially through
activating Nrf2. For example, curcumin protects against focal
ischemia of the cerebrum through upregulation of Nrf2 [16], and
oltipraz protects against ANIT-induced cholestasis through Nrf2
activation [17].
These data suggest potential therapeutic applications of the
Keap1-Nrf2 pathway, and thus Nrf2 is a promising drug target in
the treatment of oxidative/electrophilic stress-induced diseases. A
quantitative bioassay evaluating the induction of NAD(P)H:qui-
none oxidoreductase 1 (Nqo1), the prototypical Nrf2 target gene,
in Hepa1c1c7 murine hepatoma cells was developed and still
remains a major screening tool for potential activators of the
Keap1-Nrf2 pathway [18]. To date, a number of compounds with
diverse chemical structures have been shown to activate Keap1-
Nrf2, including oxidizable diphenols (tBHQ), dithiolethiones
(oltipraz), isothiocyanates (sulforaphane), and Michael acceptors
(curcumin, cinnamates, and chalcones) [19]. In an effort to
develop more potent and effective activators of the Keap1-Nrf2
pathway, chemical derivatives of known active compounds were
synthesized and screened. The most potent known Nrf2 activator,
2-cyano-3,12-dioxoolean-1,9-bien-28-oic acid imidazole (CDDO-
Im), is a semisynthetic triterpenoids derived from oleanolic acid
[20]. Based on the structure-activity relationship analyses of the
oleanolic triterpenoids, (6)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-
trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthrene-
2,6-dicarbonitrile (TBE-31), was synthesized. Both CDDO-Im and
TBE-31 activate the Keap1-Nrf2 pathway at nano-molar concen-
trations in vitro and in vivo [21].
Despite the discovery of a few potent Nrf2 activators (CDDO
compounds and TBE-31), there is limited information about the
chemical scaffolds that can potentially activate Nrf2. Recently,
AREc32 cells were engineered. AREc32 cells, which are derived
from MCF7 human breast cancer cells, are stably transfected with
a luciferase reporter gene construct under the control of eight
copies of rat Gsta2 AREs in the promoter region [22]. The
AREc32 cells provide a rapid and convenient quantification of
Nrf2-ARE induction by chemicals, and makes large scale-
screening of Nrf2 activators possible.
The aim of the present study was to develop a high-throughput
assay to evaluate Nrf2 activation using the AREc32 cells, screen a
library of 47,000 compounds, and to find compounds that are
potent and effective activators of Nrf2. In addition, through
structural activity relationship analyses, the present study also
aimed to discover novel chemical scaffolds that are likely to
activate the Keap1-Nrf2-ARE pathway. Results from this screen-
ing identified strong Nrf2 activators, and provide novel insights
into chemical scaffolds that might detoxify oxidative/electrophilic
stress and prevent oxidative/electrophilic stress-induced toxicity
and carcinogenesis.
Materials and Methods
Cell growth and maintenance
The AREc32 cells were obtained from CRX biosciences
(Dundee, Scotland, UK). The AREc32 are a stable cell line
derived from the human MCF7 breast carcinoma cell line with a
transfected luciferase gene construct that under the control of eight
copies of rat Gsta2 AREs in the promoter region [23]. AREc32
cells were maintained in Dulbecco’s Modified Eagle’s medium
(DMEM) containing glutamax supplemented with 10% fetal calf
serum and the antibiotic G418 (Life Technologies Corporation,
Carlsbad, CA). The cells were grown at 37uC in the presence of
5% CO2.
AREc32 cells were seeded into 384-well plates (flat-bottom
white, opaque, sterile, with lids) at a density of 3,500 cells/well
using a Wellmate bulk dispenser (Thermo Fisher Scientific,
Waltham, MA) in 50 mL of complete media per well. Cell plates
were incubated at room temperature for 30 min following seeding
to allow for even cell settling. Cell plates were then incubated at
37uC, 5% CO2 in a 95% humidified incubator for 20 hrs.
Murine hepatoma Hepa1c1c7 cells were obtained from ATCC
(Manassas, VA) and maintained in DMEM with glutamate,
supplemented with 10% (v/v) heat-inactivated FBS, penicillin (100
units/ml), and streptomycin (100 mg/ml). The cells were main-
tained at 37uC in the presence of 5% CO2.
Compound libraries and preparation
Four libraries of compounds were screened for Nrf2 activation
in the present study: 2000 compounds were obtained from
MicroSource Discovery Systems (www.msdiscovery.com/
spectrum.html), 1120 compounds were obtained from Prestwick
Chemical Library (Prestwick Chemical, Washington, DC), 1920
compounds were obtained from the University of Kansas Center
of Excellence in Chemical Methodologies & Library Development
(KU-CMLD), and 41,888 compounds were obtained from
ChemBridge Small Molecule Library (ChemBridge Corporation,
San Diego, CA).
The four libraries of compounds were stored at 2859 mM in
100% DMSO, and 175 nL of each compound was transferred to
the 50 mL cell culture medium in the receiving well. Chembridge
library compounds were dispensed by the Matrix PlateMate Plus
automated nanoliter capacity liquid handler (Thermo Fisher
Scientific, Waltham, MA), followed by three gentle mixings.
Compounds from MicroSource, Prestwick, and CMLD libraries,
as well as the compounds for the concentration-response
validation, were dispensed by Labcyte Echo 550 Compound
Reformatter (Labcyte Inc., Sunnyvale, CA), which allows the
accurate transfer of small volumes of liquid. The final concentra-
tion of each chemical in the full library screen was 10.0 mM, with a
DMSO content of 0.35%.
Quantification of ARE activation by Promega Steady-Glo
luciferase assay system
AREc32 cells were exposed to library compounds for 24 hrs at
37uC, 5% CO2 in a 95% humidified incubator, then removed
from the incubator and left at room temperature for 20 min to
equilibrate the plate and its contents to room temperature. The
Matrix Wellmate dispensed Steady-Glo luciferase assay reagent
(Promega, Madison, WI) to all cells, 10 mL per well, and plates
were shaken for 1 min at 1600 rpm. The luminescence intensities
were read 30 min later on a Tecan Safire2 microplate reader
(Männedorf, Switzerland). The luminescence values used for data
analysis were derived from a luciferase reaction (Figure S1). The
Steady-Glo reagent produces cell lysis and generation of a
luminescent signal, which is proportional to ARE activation, via
the luciferase reporter in the AREc32 cell line.
Four controls were used on each plate of cells: (1) cells treated
with tBHQ, a known ARE activator (positive control), (2) cells
treated with CDDO-Im, a very potent activator of Nrf2/ARE
(positive control), (3) cells in media containing 0.35% DMSO
(vehicle control), and (4) cells in media containing no DMSO
(control cells) to measure background luminescence. The plate
map for the controls is displayed in Figure S2.
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Z9 factor for Pass/Fail Criterion
The positive and negative controls were required to assure
uniformity from plate to plate, and from screening batch to batch.
The controls were used to calculate a Z9 factor value for each
plate, a measure of assay robustness and variability popularly used
for high throughput screening. The Z9 factor compares the
baseline background (minimum ARE signal) from the DMSO
vehicle control, and the maximum signal of response of the
positive controls tBHQ and CDDO-Im [24,25]. The Z9 factor
formula relies on the mean and standard deviation of the
maximum signal and the minimum baseline, as shown in Figure
S3. In this assay, screening plates were expected to have a Z9 value
equal to or greater than 0.6. Plates with Z9 values below 0.4 were
individually investigated, and rejected or repeated on a plate by
plate basis.
Quantification of Nqo1 mRNA in Hepa1c1c7 cells
The top 30 hits from the primary screen were further validated
by quantifying the mRNA of Nqo1, a prototypical Nrf2 target
gene, in Hepa1c1c7 cells by real time-PCR. Cells were grown in
24-well plates at a density of 30,000 cells per well for 12 hrs, and
subsequently incubated with test compounds at 6 concentrations
(0.1–3 mM) for 24 hrs. After incubation, the medium was decanted
and total RNA was isolated using RNAzol B reagent (Tel Test,
Inc., Friendswood, TX). cDNA was synthesized with a High
Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA)
from total RNA, and the resulting cDNA was used for real-time
PCR to quantify Nqo1 mRNA, with b-actin used as the internal
control. The primer sequences for Nqo1 and b-actin are listed in
Table S1.
Compound structure clustering analysis
Preliminary hit clustering was based on EC50 values from the
concentration-response curves of the top 240 compounds, and
accomplished via the Selector program from Tripos via the Jarvis
Patrick routine, using default parameters. From each preliminary
cluster, the largest conserved substructure present in at least half of
the cluster members was identified. Each cluster was then
manually edited to remove compounds that did not contain the
largest conserved substructure identified in the previous step.
Compounds that had not originally been selected to a given cluster
but containing the cluster’s characteristic conserved substructure
were then added to the cluster.
Induction of Nqo1 by the top 30 hits from the primary
screening in Hepa1c1c7 cells
Hepac1c7 cells were seeded into 24-well plates at a density of
30,000 cells/well in 1 mL complete media per well and cultured
overnight to allow attachment. Cells were treated the next day
with the top 30 compounds from the primary screening and were
harvested 24 h after treatment. Total RNA samples were isolated
by using RNAzol B reagent (Tel-Test, Inc., Friendswood, TX)
according to the manufacturer’s protocol, and were reverse-
transcribed into cDNA by High Capacity cDNA Archive Kits
(Applied Biosystems, Foster City, CA). The resulting cDNA was
used for real-time PCR analysis using SYBRH Green PCR Master
Mix in a 7900HT Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA). Oligonucleotide primers specific to
mouse b-actin and Nqo1 are shown in Table S1.
Results
Luciferase assay signal stability
Batch processing of 384-well plates for the HTS library screen
requires the readout signal to be steady for at least 30 min, and
preferably one hr to minimize timing effects. To test the luciferase
assay signal stability of AREc32 cells, they were seeded at 3,000
cells/well in a 384-well plate, and tBHQ, a typical Nrf2 activator,
was added to cells to make final concentrations of 0, 10, 20, or
80 mM. All wells had a final DMSO concentration of 0.5%.
Twenty-four hrs after treatment, luciferase activity was assessed
using the Steady-Glo luciferase assay with luminescence readout.
The luminescence signal was recorded 30 min after cell lysis, and
was quantified repeatedly every 30 min for six hrs. As shown in
Fig. 1A, the luminescent signal was strong and stable for over one
and half hrs after adding the luciferase reagent.
Optimization of AREc32 cells seeding density
To determine the optimal seeding density of AREc32 cells
under screening conditions, cells were seeded at a range of 1,000–
10,000 cells/well in a 384-well plate, and were treated with tBHQ
or DMSO vehicle (0–50 mM tBHQ, 0.5% DMSO). Twenty-four
hrs after treatment, luciferase activity was assessed with lumines-
cence readout. The luminescent signal was quantified 30 min after
adding the luciferase reagent to the cells. Data is presented as fold
increase in luminescence by tBHQ over vehicle control. As shown
in Fig. 1B, 3,000–3,500 cells/well provided optimal activation of
the ARE-luciferase construct by tBHQ.
The effect of DMSO on cell viability and assay sensitivity
Because the compounds are maintained in 100% DMSO, the
effect of DMSO on viability and assay sensitivity of AREc32 cells
was investigated. Cell viability was unaffected by DMSO below
0.75% (data not shown). To test the effect of DMSO on assay
sensitivity, cells were seeded at 3,000 cells/well in a 384-well plate
and a mixture of media and DMSO was added to each well to
achieve a final DMSO content of 0%–10%. Additionally, 5 mL of
media with or without tBHQ was added immediately following
addition of DMSO. Twenty-four hrs after treatment, luciferase
activity was assessed by the luminescence readout. As shown in
Fig. 1C, the ability of tBHQ to activate the luciferase reporter
construct was hindered by DMSO concentration above 1%. To
avoid cell stress that may activate undesired molecular pathways,
0.5% DMSO was selected as the maximum tolerable concentra-
tion of DMSO in the cell culture medium.
Dose-response activation of ARE-luciferase reporter
construct in AREc32 cells by known Nrf2 activators
To validate the ARE-luciferase reporter assay, tBHQ and
CDDO-Im, two prototypical Nrf2 activators were tested in the
AREc32 cells. Cells were seeded at 3,000 cells/well in a 384-well
plate and treated with DMSO vehicle or compound (0–100 mM
for tBHQ and 0–2 mM for CDDO-Im). Twenty-four hrs after
treatment, luciferase activity was assessed by quantifying the
luminescent intensity. As shown in Fig. 2A, both tBHQ and
CDDO-Im increased the luminescence signal in a dose-dependent
manner, with over a 70-fold increase in luminescence at 100 mM
(tBHQ) or 300 nM (CDDO-Im).
Other known Nrf2 activators, namely curcumin, sulforaphene,
and genistein, also increased the luminescence signal in AREc32
cells in a concentration-dependent manner (data not shown).
High-Throughput Screening of Nrf2 Activators
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Pilot screening of 5040 compounds from the
Microsource, Prestwick, and CMLD libraries
To further validate the ARE-luciferase reporter assay in a high-
throughput manner, 1,120 compounds from the Prestwick library
were screened in the AREc32 cells at seven concentrations and
within a range of 0.25–16 mM. Twenty-one compounds (top 1.9%)
increased the luminescence signal in a concentration-dependent
manner, with the maximum fold-induction value higher or
comparable to tBHQ (data not shown). The 2,000 compounds
from the Microsource library and 1920 compounds from the
CMLD library were screened at a final concentration of 10 mM.
The fold-induction of the luminescent signals of the tested
compounds is shown in Fig. 2B, with the fold-induction values
of positive controls for comparison. Specifically, the fold-induction
values of compounds in Microsource and CMLD libraries were
tested in a final concentration of 10 mM, and compounds in the
Prestwick library were treated at 8 mM.
The Z9 factor measure of assay robustness and variability was
plotted for the 16 validation library plates (Fig. 2 C). The Z9 scores
for the validation library screening plates of libraries confirmed the
Z9 score of the screen was greater than 0.6 for all plates,
confirming the quality of the assay methodology.
Full screening of 47,000 compounds from the
Microsource, Prestwick, and Chembridge Libraries
After the luciferase-based reporter assay was validated in a high-
throughput system, the full library containing 47,000 compounds
were screened using this assay. The fold increase in luminescence,
indicative of Nrf2 activation by compounds in AREc32 cells, was
plotted against each individual well of the libraries (Fig. 3A). The
majority of compounds did not activate Nrf2, and were densely
packed at the bottom of the scatterplot. Only the top 0.5% hits
(238 compounds) increased the luminescence more than 14.4-fold.
A histogram summarizing the frequency distribution of the ability
of the compounds to increase luminescence over the DMSO
control is shown in Fig. 3B. The majority of compounds did not
activate Nrf2. The top 1% hits (485 compounds) increased the
luminescence more than 9-fold, the top 0.5% hits (255
compounds) increased the luminescence more than 14.4-fold, the
top 0.25% hits (119 compounds) increased the luminescence more
than 20-fold, and the top 0.1% hits (48 compounds) increased the
luminescent signal more than 28-fold.
Dose-response curves for the 4 compounds with the
highest maximal ARE activation
The 255 most active compounds (top 0.5% hit) from the full
library screening were retested at multiple concentrations (0.14–
30 mM), and 91% of them (247 compounds) activated the Nrf2
pathway in a concentration-dependent manner. Among those 247
validated hits, 18 compounds were shown to be extremely effective
and each produced a maximum fold-activation higher than that of
CDDO-Im. The concentration-response curves of the top 4
compounds are shown in Fig. 4A. Compound KU0006807
increased the luminescence signal 125-fold at 18 mM; KU
0105510 increased the luminescence signal 119-fold at 18 mM;
KU0103737 increased the luminescence signal 115-fold at
3.9 mM; and KU0017619 increased the luminescence signal
111-fold at 18 mM. The chemical structures of KU0006807, KU
0105510, KU0103737, and KU0017619 are shown in Fig. 4B.
Dose-response curves for the 4 compounds with the
lowest EC50 for Nrf2-ARE activation
Among those 247 validated hits from screening the full library, 6
compounds were shown to be extremely potent and had EC50
values lower than 1 mM. However, none of the compounds tested
had an EC50 value lower than that of CDDO-Im. The
concentration-response curves of the top 4 compounds are shown
in Fig. 4C. KU0009102 had an EC50 value as 0.7 mM, and
maximum Nrf2 activation of 74-fold; KU0008241 had an EC50
value as 0.9 mM, and maximum Nrf2 activation of 46-fold;
KU0025955 had an EC50 value as 0.9 mM, and maximum Nrf2
activation of 72-fold; and KU0012935 had an EC50 value as
1 mM, with maximum Nrf2 activation of 47-fold. The chemical
Figure 1. Development and optimization of an ARE induction
assay in AREc32 Cells. (A) The luciferase assay signal stability in the
presence of 0, 10, 20, or 80 mM tBHQ.(B) The effect of AREc32 cells
seeding density on the luciferase assay sensitivity in the presence of 0,
10, 20, or 80 mM. (C) The effect of DMSO concentration on the luciferase
assay sensitivity using a range of 0%–10% DMSO in the presence or
absence of 0 or 10 mM tBHQ.
doi:10.1371/journal.pone.0044686.g001
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structure of KU0009102, KU0008241, KU0025955, and
KU0012935 are shown in Fig. 4D.
Structure clusters of hits from the primary screening
The chemical structures of the top 247 hits fall into four clusters.
The chemical scaffolds of the clusters, as well as the compound
numbers are noted in Fig. 5. Cluster 1 contains 80 structures that
are related diaryl amides and diaryl ureas, and 10 of them were
very potent with EC50 values lower than 2 mM. Cluster 2 contains
22 structure-related oxazoles and thiazoles, and eight of them were
highly potent with EC50 values lower than 2 mM. Cluster 3
contains 23 structure-related pyranones and thiapyranones,
including one highly potent compound with an EC50 lower than
2 mM. Cluster 4 contains 22 structure-related pyridinones,
pyridazinones, and pyrimidones, but none had EC50 values lower
than 2 mM.
Figure 2. Validation of the ARE induction assay using known Nrf2 activators and through pilot screening. (A) Concentration-response
curves of tBHQ and CDDO-Im to increase the luminescent signal in AREc32 cells. (B) Activity spread of compounds in Microsource, Prestwick, and
CMLD libraries together with positive controls. Compounds in Microsource and CMLD libraries were tested at 10 mM, and compounds in Prestwick
library were tested at 8 mM. (C) Z9 scores for 16 pilot screening plates.
doi:10.1371/journal.pone.0044686.g002
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Induction of Nqo1 by the top 30 hits from the primary
screening in Hepa1c1c7 cells
To validate the active compounds using a different technique
than the ARE-luciferase assay, and to determine the ability of
active compounds to induce cytoprotective genes, a secondary
screen assay was developed to quantify Nqo1 mRNA in
Hepa1c1c7 cells. As shown in Fig. 6A, both tBHQ and CDDO-
Im increased Nqo1 mRNA in a concentration-dependent manner,
with over a 7-fold increase in Nqo1 mRNA with 30 mM tBHQ or
100 nM CDDO-Im.
Nineteen compounds with the lowest EC50 values and 14
compounds with the highest maximum increase of luminescence
signal from the primary screen were selected for the secondary
screen. Three compounds (KU0002640, KU0003452, and
KU0013654) were shown to activate Nrf2 at both the lowest
EC50 concentrations and the highest maximum increase of
luminescence. Thus, 30 compounds were screened in Hepa1c1c7
cells at six concentrations (0–3 mM). Among those 30 compounds,
17 of them increased Nqo1 mRNA in a concentration-dependent
manner, and the concentration-response curves of the most
effective four compounds are shown in Fig. 6B. Specifically,
KU002640, which has both the lowest EC50 and highest Nrf2
activation in the primary screen, also increased Nqo1 mRNA the
most in the secondary screen.
Discussion
The present study describes the development, implementation,
and validation of a high-throughput screen to identify activators of
the Keap1-Nrf2-ARE pathway. Using a luciferase-based assay
driven by AREs in the promoter region of the luciferase gene, the
AREc32 cells provides a rapid and convenient quantification of
Figure 3. Full library screening for Nrf2 activators through ARE induction assay in AREc32 cells. (A) The scatterplot distribution of the
screening actives from the ARE library screen was calculated using data from the Chembridge, Prestwick, Microsource, and CMLD library compounds.
The fold increase in luminescence, indicative of ARE activation by compounds in AREc32 cells, is plotted against each individual well of the libraries.
(B) Frequency distribution of the Chembridge, Prestwick, Microsource, and CMLD library compounds to increase the luminescent signal in AREc32
cells.
doi:10.1371/journal.pone.0044686.g003
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Nrf2-ARE induction by small molecules, and made large scale-
screening for Nrf2 activators possible.
In contrast to many focused-screenings for Nrf2 activators in
previous reports, which compared the efficacy and potency of
potential Nrf2 activators that are derived from a single chemical
scaffold [26,27,28], the present study screened 47,000 chemicals
with diverse sources and chemical structures. This experimental
design increased the chances of identifying novel chemical
scaffolds for analogs that could potentially be further developed
to have improved potency, efficacy, and pharmacokinetics. The
present study summarizes four novel chemical scaffolds that
clustered in the top 0.5% hits: (1) diaryl amides and diaryl ureas,
(2) oxazoles and thiazoles, (3) pyranones and thiapyranones, and
(4) pyridinones and pyridazinones. Among these four chemical
clusters, cluster 1 contains the greatest number of the top 0.5% hits
(80 hits in cluster 1, 22 hits in cluster 2, 23 hits in cluster 3, and 22
hits in cluster 4), and contains the most number of hits with EC50
values less than 1.4 mM (5 hits in cluster 1, 4 hits in cluster 2, and
no hits in cluster 3 or cluster 4). Thus, the chemical scaffold of
cluster 1 may have the greatest potential for designing chemical
analogs and to develop strong Nrf2 activators.
The present study validates the top 0.5% hits (238 compounds)
with eleven concentrations in a wide range of concentrations.
Thus, the EC50 value for activating Nrf2 of each compound is
available, which makes the comparison of the potency of the
compounds possible. In addition, the concentration-response assay
also generates the highest maximum fold-increase in lumines-
cence, and the ranking of the top hits was modified accordingly.
For example, KU0105510 was shown to increase the lumines-
cence 26-fold at 10 mM. However, the concentration-response
Figure 4. Concentration-response curves of the most effective and potent compounds. (A) Concentration-response curves and (B)
chemical structures of top four compounds with greatest maximum fold-increase in luminescent signal. (C) Concentration-response curves and (D)
chemical structures of top four compounds with lowest EC50. AREc32 cells were treated with compound (0.01–30 mM) or DMSO vehicle. 24 hours
after treatment, luciferase activity was assessed using the Steady-Glo luciferase assay with luminescence readout. The luminescence of each well was
divided by the median luminescence of the DMSO vehicle control wells to generate the fold ARE activation.
doi:10.1371/journal.pone.0044686.g004
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assay shows that KU0105510 can increase the luminescence 119-
fold at 18 mM, which makes it the second most effective hit in the
full library (Fig. 4A). Some extremely potent compounds activated
Nrf2 at low concentrations, and the activity decreased at higher
concentrations. For example, KU0103737 increased the lumines-
cent signal by 18-fold at 10 mM. However, the concentration-
response assay shows that KU0103737 induced the luminescent
signal most at 3.9 mM (116-fold), and the induction was blunted at
higher concentrations (Fig. 4). Collectively, the concentration-
response assay identified extremely effective and potent com-
pounds among the top 0.5% hits.
The concentration-response studies also revealed two distinct
patterns in Nrf2-ARE induction. The first battery of hits (example:
KU0103737 and KU0105510) increased the luminescent signal
markedly (over 110-fold), but the increase was blunted at higher
concentrations after reaching the maximum fold-increase. The
second battery of hits (example: KU0009102 and KU0003004)
increased the luminescence moderately (70-fold), reached a
plateau, but also increased the luminescence moderately (60–70
fold) at higher concentrations (6–30 mM). Compared with the first
battery of hits, the second battery of hits may be more plausible for
drug development to have a steady effect over a wide range of
drug concentrations.
For luciferase reporter-based assays, one major concern is
identifying false active compounds that increase the luminescent
signal not through activation of the target, but through stabiliza-
tion of the luciferase enzyme. Therefore, a counter screen was
performed to rule out such false positive hits. The 196 hits from
the primary screen were randomly selected and tested for the
capability of stabilizing purified firefly luciferase. Among these 196
hits, only 11 hits tested stabilized luciferase enzyme, and thus
could be false positives (data not shown).
Figure 5. Chemical scaffolds clustered in the top 247 validated
hits from the primary screening. Preliminary hit clustering was
based on the EC50 value from the concentration-response curves of the
top 240 compounds, and accomplished via the Selector program from
Tripos via the Jarvis Patrick routine, using default parameters.
doi:10.1371/journal.pone.0044686.g005
Figure 6. Concentration-response curves of known Nrf2
activators and most active compounds from the secondary
screening. Concentration-response curves of (A) tBHQ and CDDO-Im,
and (B) top 4 compounds from the secondary screening. Hepa1c1c7
cells were treated with compound (0.01–3 mM) or DMSO vehicle.
24 hours after treatment, mRNA of Nqo1 was quantified using reverse
transcription q-PCR analysis. Fold-increase in Nqo1 mRNA was
normalized by cells treated with DMSO vehicle.
doi:10.1371/journal.pone.0044686.g006
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To investigate whether the validated hits from the primary
screen can also induce Nrf2 target genes, a secondary screen was
designed to test the ability of the hit compounds to induce Nqo1,
the prototypical Nrf2 target gene, in Hepa1c1c7 cells. The results
shows that 17 of the 30 compounds increase Nqo1 mRNA in a
concentration-dependent manner. The relatively low validation
rate may result from four reasons. First, once Nrf2 translocates
into the nucleus upon activation, Nrf2 heterodimerizes with other
transcription factors (example: small Mafs, c-Jun, and c-Fos) and
Nrf2-ARE signaling is affected by these Nrf2-binding transcription
factors. Recently, ERa was shown to bind Nrf2 in the nucleus and
suppress Nrf2-dependent gene transcription [29]. Thus, the
different responses of AREc32 cells and Hepa1c1c7 cells to
Nrf2-ARE activation may result from distinct estrogen signaling in
these two cell lines (human breast cancer cells versus mouse
hepatoma cells). Secondly, the luciferase gene in AREc32 cells
contains eight AREs in the promoter region [23]. However, mouse
Nqo1 gene is induced through one functional ARE [30]. Thus, the
secondary assay may be less sensitive to Nrf2 activators than the
primary assay. Lastly, the AREc32 and Hepa1c1c7 cells may have
distinct expression of uptake transporters, resulting in different
bioavailability of the test compounds.
As for all transcription activation-based assays, neither the
primary nor the secondary screening assay provide information
about how active compounds activate the Keap1-Nrf2-ARE
pathway. However, previous reports suggest that these active
compounds may activate the Keap1-Nrf2-ARE pathway through
multiple mechanisms [31], as shown in Fig. 7. Some active
compounds may disrupt binding of Keap1 to Nrf2, leading to the
release of Nrf2, and allowing Nrf2 to translocate to the nucleus
[32]. Some active compounds may lead to ubiquitination of
Keap1 instead of Nrf2, and facilitate Nrf2 accumulation [33].
Some active compounds may cause an inactivation of the Nrf2
export signal, increasing Nrf2 accumulation in the nucleus [34].
Some active compounds may increase nuclear export of Bach1,
which competes with Nrf2 for small Maf binding [35]. Lastly,
some active compounds may activate protein kinase cascades
(example: MAPK and PI3K) [36], causing enhanced Nrf2
phosphorylation.
In conclusion, the present study documents the development,
implementation, and validation of a high-throughput screen to
identify activators of the Keap1-Nrf2-ARE pathway. Eight
compounds that are extremely potent and effective in activating
Nrf2 were identified. In addition, the present study also
summarized four novel chemical scaffolds that may have utility
in rational design of Nrf2-activating compounds for therapy of
oxidative/electrophilic stress-induced diseases.
Supporting Information
Figure S1 Experimental design for primary screening.
The AREc32 cell line was exposed to library compounds for
24 hours at, then removed from the incubator and left at room
temperature for 20 minutes to equilibrate the plate and its
contents to room temperature. The Matrix Wellmate dispensed
Steady-Glo luciferase assay reagent to all cells, 10 mL per well, and
plates were shaken for 1 minutes at speed 1600 rpm. 30 min later,
the luminescence intensities were read on the Tecan Safire2
microplate reader. The luminescence values used for data analysis
were derived a luciferase reaction.
(TIF)
Figure S2 Plate design for primary screening. No
compounds were present in the first two columns of plates to
allow room for in-plate controls. Grey: library compound
containing wells. Glue: cells treated with 10 mM tBHQ. Pink:
cells treated with 100 nM CDDO-Im. Orange: cells in media
containing 0.35% DMSO. Yellow: cells in media containing no
DMSO.
(TIF)
Figure S3 Calculation formulation of Z9 factor.
(JPG)
Table S1 Oligonucleotide sequences for primers spe-
cific for mouse b-actin and Nqo1.
(DOCX)
Figure 7. Hypothetical modes of action of actives compounds. Four potential mechanisms of action for hit compounds to activate Keap1-
Nrf2-ARE pathway. Hit compounds can disrupt binding of Keap1 to Nrf2, facilitate Keap1 ubiquitination, inactivate Nrf2 export signaling, or activate
protein kinase cascades for Nrf2 phosphorylation.
doi:10.1371/journal.pone.0044686.g007
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